Report Stack

Our Formula For Mechanism Of Action Is So Effective We’d Patent It If We Could

Posted on Updated on

Pharm Insights-Coverpage

DelveInsight’s Mechanism of Action Reports has become the Success Reason for the Leading Pharma Companies

In this competitive world, everybody wants to get aware of what others are doing in their sectors and what strategic drivers are followed by the others for the successful future milestones. But the drug future is only dependent on one thing and that is how much efficacy it is showing through its mechanism of action to improve the medical condition. So utilizing the most effective targets and technology, the drug can do million dollar business.

DelveInsight released Mechanism of Action reports provides the targets-mode of action based information-across all the therapy under research work, pipeline products across all the companies, current technology, molecule type, stage, company finances, comparative analysis and therapeutic assessment at every step. These Reports propose specific strategies that could have the most substantial impact in improving R&D productivity.

“We are really happy that our reports are showing potential in the market. We have become a strategic partner for the Pharma Companies worldwide” said Dr. B.K. Agrawal, Managing Partner at DelveInsight Business Research.

These Reports highlights therapeutic targets and their mode of action; for instance Inflammatory targets: Reversible Anticholinesterases, Sphingosine 1-Phosphate (S1P) Inhibitors, c-jun-N-Terminal Kinase (JNK) inhibitors, Cancer Targets: Gamma Secretase inhibitors, IL-13 Receptor Antagonists and many more…..

DelveInsight’s Mechanism of Action reports is not only gaining importance but also has become the most known among the clients.

These reports are available with many resellers like Report Linkers, Report Buyers, Research moz, ASD Reports, Report Stack, Bharat Book Bureau and Market Reports.

Ask for sample reports now!

For more information please contact info@delveinsight.com

Advertisements

Metastatic Prostate Cancer-Pipeline Insights, 2014

Posted on Updated on

DelveInsight’s,“ Metastatic Prostate Cancer-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Metastatic Prostate Cancer. This report provides information on the therapeutic development based on the Metastatic Prostate Cancer dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Scope
– The report provides a snapshot of the global therapeutic landscape of Metastatic Prostate Cancer
– The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
– Coverage of the Metastatic Prostate Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
– The report reviews key players involved in the therapeutics development for Metastatic Prostate Cancer and also provide company profiling
– The report also gives the information of dormant and discontinued pipeline projects
– Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
– Complete Pipeline intelligence and complete understanding over therapeutics development for Metastatic Prostate Cancer
– Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
– Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics
– Developing strategic initiatives to support your drug development activities.
– Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
– Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
– Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table of Contents
– Metastatic Prostate Cancer Overview
– Metastatic Prostate Cancer Pipeline Therapeutics
– Metastatic Prostate Cancer Therapeutics under Development by Companies
– Metastatic Prostate Cancer Late Stage Products (Filed and Phase III)
– Comparative Analysis
– Metastatic Prostate Cancer Mid Clinical Stage Products (Phase II)
– Comparative Analysis
– Metastatic Prostate Cancer Early Clinical Stage Products (Phase I and IND Filed)
– Comparative Analysis
– Metastatic Prostate Cancer Discovery and Pre-Clinical Stage Products
– Comparative Analysis
– Drug Candidate Profiles
– Metastatic Prostate Cancer – Therapeutics Assessment
– Assessment by Monotherapy Products
– Assessment by Combination Products
– Assessment by Route of Administration
– Assessment by Molecule Type
– Metastatic Prostate Cancer – Discontinued Products
– Metastatic Prostate Cancer – Dormant Products
– Companies Involved in Therapeutics Development for Metastatic Prostate Cancer
– Appendix
– Methodology
– Contact Us
– Disclaimer

List of Tables

– Number of Products under Development for Metastatic Prostate Cancer, 2014
– Number of Products under Development by Companies
– Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
– Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
– Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
– Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
– Drug Candidates Profiles
– Metastatic Prostate Cancer Assessment by Monotherapy Products
– Metastatic Prostate Cancer Assessment by Combination Products
– Metastatic Prostate Cancer Assessment by Route of Administration
– Metastatic Prostate Cancer Assessment by Stage and Route of Administration
– Metastatic Prostate Cancer Assessment by Molecule Type
– Metastatic Prostate Cancer Assessment by Stage and Molecule Type
– Metastatic Prostate Cancer Therapeutics – Discontinued Products
– Metastatic Prostate Cancer Therapeutics – Dormant Products
– Products under Development by Companies, 2014

List of Figures

– Number of Products under Development for Metastatic Prostate Cancer, 2014
– Late Clinical Stage Products (Filed and Phase III), 2014
– Mid Clinical Stage Products (Phase II), 2014
– Early Clinical Stage Products (Phase I and IND Filed), 2014
– Discovery and Pre-Clinical Stage Products, 2014
– Metastatic Prostate Cancer Assessment by Monotherapy Products
– Metastatic Prostate Cancer Assessment by Combination Products
– Metastatic Prostate Cancer Assessment by Route of Administration
– Metastatic Prostate Cancer Assessment by Stage and Route of Administration
– Metastatic Prostate Cancer Assessment by Molecule Type
– Metastatic Prostate Cancer Assessment by Stage and Molecule Type

Report Pricing
Single User License: $1250
Site License:$2500
Global License:$4000

For Sample Pages and Report, please contact us at info@delveinsight.com

Successful Launch of Mechanism of Action Based Pipeline Reports by DelveInsight

Posted on Updated on

Get the idea what Other Companies are doing with the Targets you are Interested In and what their progress and strategize to get the best out of it with our MOA Pipeline Reports.

After a successful launch of Drug and Indication Reports under Pharm Delve Series, DelveInsight has come up with a Pipeline Reports under brand name Pharm Insights covering 700+ Mechanism of Action reports.

Mechanism of Action Based Reports is one of a kind report which will provides comprehensive insights about pipeline drugs across this mechanism of action (MOA). This report provides information on the therapeutic development based on the certain MOA dealing with the target, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the company’s information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

“In this highly competitive world, everybody wants to understand the pace of their competitors. Mechanism of Action based reports is the key for them” said Ms Mridhu Verma, Analyst at DelveInsight.

These reports can be available through leading resellers such as Report Linker’s, Report Buyer’s and Report stack or you can directly contact at info@delveinsight.com.

Pharm Insights-Coverpage